Supplementary Figure S5 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial Article Swipe

PDF

Yihebali Chi , Yuan Zhang , Feng Shi , Zhuming Guo , Minghua Ge , Jiewu Zhang , Zhendong Li , Xiaohong Zhou , Rui Huang , Xiaohong Chen , Hui Liu , Dapeng Li , Pingzhang Tang ·

YOU? · · 2025 · Open Access · · DOI: https://doi.org/10.1158/1078-0432.30710290

Best changes in the sum of longest diameters of target lesions for the anlotinib group and the placebo group. Purplish red: confirmed partial response; blue: stable disease lasting at least 4 week.

Related Topics

Public Figure

Gayniggers From Outer Space

From Hilde, With Love

Girl From The North Country (Musical)

Quotations From Chairman Mao Tse-Tung

Far From The Madding Crowd (2015 Film)

Jenny From The Block

The Last Letter From Your Lover

Historical Figure

2025 World Figure Skating Championships

Action Figure

Friends From College

Douglas Macarthur's Escape From The Philippines

Work From Home (Song)

Concepts

No concepts available.

Metadata

Type: article
Landing Page: https://doi.org/10.1158/1078-0432.30710290
PDF: https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_S5_from_Anlotinib_in_Locally_Advanced_or_Metastatic_Radioiodine-Refractory_Differentiated_Thyroid_Carcinoma_A_Randomized_Double-Blind_Multicenter_Phase_II_Trial/30710290/1/files/59835124.pdf
OA Status: gold
OpenAlex ID: https://openalex.org/W4416630283

All OpenAlex metadata

Raw OpenAlex JSON

OpenAlex ID: https://openalex.org/W4416630283

Canonical identifier for this work in OpenAlex
DOI: https://doi.org/10.1158/1078-0432.30710290

Digital Object Identifier
Title: Supplementary Figure S5 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial

Work title
Type: article

OpenAlex work type
Publication year: 2025

Year of publication
Publication date: 2025-11-25

Full publication date if available
Authors: Yihebali Chi, Yuan Zhang, Feng Shi, Zhuming Guo, Minghua Ge, Jiewu Zhang, Zhendong Li, Xiaohong Zhou, Rui Huang, Xiaohong Chen, Hui Liu, Dapeng Li, Pingzhang Tang

List of authors in order
Landing page: https://doi.org/10.1158/1078-0432.30710290

Publisher landing page
PDF URL: https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_S5_from_Anlotinib_in_Locally_Advanced_or_Metastatic_Radioiodine-Refractory_Differentiated_Thyroid_Carcinoma_A_Randomized_Double-Blind_Multicenter_Phase_II_Trial/30710290/1/files/59835124.pdf

Direct link to full text PDF
Open access: Yes

Whether a free full text is available
OA status: gold

Open access status per OpenAlex
OA URL: https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_S5_from_Anlotinib_in_Locally_Advanced_or_Metastatic_Radioiodine-Refractory_Differentiated_Thyroid_Carcinoma_A_Randomized_Double-Blind_Multicenter_Phase_II_Trial/30710290/1/files/59835124.pdf

Direct OA link when available
Cited by: 0

Total citation count in OpenAlex

Full payload

id	https://openalex.org/W4416630283
doi	https://doi.org/10.1158/1078-0432.30710290
ids.doi	https://doi.org/10.1158/1078-0432.30710290
ids.openalex	https://openalex.org/W4416630283
fwci
type	article
title	Supplementary Figure S5 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
biblio.issue
biblio.volume
biblio.last_page
biblio.first_page
is_xpac	False
apc_list
apc_paid
language
locations[0].id	doi:10.1158/1078-0432.30710290
locations[0].is_oa	True
locations[0].source
locations[0].license	cc-by
locations[0].pdf_url	https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_S5_from_Anlotinib_in_Locally_Advanced_or_Metastatic_Radioiodine-Refractory_Differentiated_Thyroid_Carcinoma_A_Randomized_Double-Blind_Multicenter_Phase_II_Trial/30710290/1/files/59835124.pdf
locations[0].version	acceptedVersion
locations[0].raw_type	posted-content
locations[0].license_id	https://openalex.org/licenses/cc-by
locations[0].is_accepted	True
locations[0].is_published	False
locations[0].raw_source_name
locations[0].landing_page_url	https://doi.org/10.1158/1078-0432.30710290
indexed_in	crossref
authorships[0].author.id	https://openalex.org/A5076582862
authorships[0].author.orcid	https://orcid.org/0000-0002-8381-3554
authorships[0].author.display_name	Yihebali Chi
authorships[0].author_position	first
authorships[0].raw_author_name	Yihebali Chi
authorships[0].is_corresponding	False
authorships[1].author.id	https://openalex.org/A5100769699
authorships[1].author.orcid	https://orcid.org/0009-0009-7507-3590
authorships[1].author.display_name	Yuan Zhang
authorships[1].author_position	middle
authorships[1].raw_author_name	Yuan Zhang
authorships[1].is_corresponding	False
authorships[2].author.id
authorships[2].author.orcid	https://orcid.org/0009-0002-3600-3126
authorships[2].author.display_name
authorships[2].author_position	middle
authorships[2].raw_author_name	Feng Shi
authorships[2].is_corresponding	False
authorships[3].author.id	https://openalex.org/A5088323967
authorships[3].author.orcid	https://orcid.org/0009-0007-0586-6099
authorships[3].author.display_name	Zhuming Guo
authorships[3].author_position	middle
authorships[3].raw_author_name	Zhuming Guo
authorships[3].is_corresponding	False
authorships[4].author.id	https://openalex.org/A5005066823
authorships[4].author.orcid	https://orcid.org/0000-0001-6726-6418
authorships[4].author.display_name	Minghua Ge
authorships[4].author_position	middle
authorships[4].raw_author_name	Minghua Ge
authorships[4].is_corresponding	False
authorships[5].author.id	https://openalex.org/A5003118713
authorships[5].author.orcid	https://orcid.org/0009-0008-0088-8683
authorships[5].author.display_name	Jiewu Zhang
authorships[5].author_position	middle
authorships[5].raw_author_name	Jiewu Zhang
authorships[5].is_corresponding	False
authorships[6].author.id	https://openalex.org/A5007073787
authorships[6].author.orcid	https://orcid.org/0000-0002-3930-2888
authorships[6].author.display_name	Zhendong Li
authorships[6].author_position	middle
authorships[6].raw_author_name	Zhendong Li
authorships[6].is_corresponding	False
authorships[7].author.id	https://openalex.org/A5060184563
authorships[7].author.orcid	https://orcid.org/0009-0001-2489-4171
authorships[7].author.display_name	Xiaohong Zhou
authorships[7].author_position	middle
authorships[7].raw_author_name	Xiaohong Zhou
authorships[7].is_corresponding	False
authorships[8].author.id	https://openalex.org/A5082728678
authorships[8].author.orcid	https://orcid.org/0000-0003-3191-0528
authorships[8].author.display_name	Rui Huang
authorships[8].author_position	middle
authorships[8].raw_author_name	Rui Huang
authorships[8].is_corresponding	False
authorships[9].author.id	https://openalex.org/A5101985612
authorships[9].author.orcid	https://orcid.org/0000-0002-3825-2647
authorships[9].author.display_name	Xiaohong Chen
authorships[9].author_position	last
authorships[9].raw_author_name	Xiaohong Chen
authorships[9].is_corresponding	False
authorships[10].author.id	https://openalex.org/A5055922518
authorships[10].author.orcid	https://orcid.org/0009-0003-1713-4363
authorships[10].author.display_name	Hui Liu
authorships[10].author_position	middle
authorships[10].raw_author_name	Hui Liu
authorships[10].is_corresponding	False
authorships[11].author.id	https://openalex.org/A5100419606
authorships[11].author.orcid	https://orcid.org/0000-0003-2861-3899
authorships[11].author.display_name	Dapeng Li
authorships[11].author_position	middle
authorships[11].raw_author_name	Dapeng Li
authorships[11].is_corresponding	False
authorships[12].author.id	https://openalex.org/A5052607264
authorships[12].author.orcid	https://orcid.org/0009-0009-8612-3928
authorships[12].author.display_name	Pingzhang Tang
authorships[12].author_position	middle
authorships[12].raw_author_name	Pingzhang Tang
authorships[12].is_corresponding	False
has_content.pdf	True
has_content.grobid_xml	False
is_paratext	False
open_access.is_oa	True
open_access.oa_url	https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_S5_from_Anlotinib_in_Locally_Advanced_or_Metastatic_Radioiodine-Refractory_Differentiated_Thyroid_Carcinoma_A_Randomized_Double-Blind_Multicenter_Phase_II_Trial/30710290/1/files/59835124.pdf
open_access.oa_status	gold
open_access.any_repository_has_fulltext	False
created_date	2025-11-25T00:00:00
display_name	Supplementary Figure S5 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
has_fulltext	False
is_retracted	False
updated_date	2025-11-28T19:05:18.588976
primary_topic
cited_by_count	0
locations_count	1
best_oa_location.id	doi:10.1158/1078-0432.30710290
best_oa_location.is_oa	True
best_oa_location.source
best_oa_location.license	cc-by
best_oa_location.pdf_url	https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_S5_from_Anlotinib_in_Locally_Advanced_or_Metastatic_Radioiodine-Refractory_Differentiated_Thyroid_Carcinoma_A_Randomized_Double-Blind_Multicenter_Phase_II_Trial/30710290/1/files/59835124.pdf
best_oa_location.version	acceptedVersion
best_oa_location.raw_type	posted-content
best_oa_location.license_id	https://openalex.org/licenses/cc-by
best_oa_location.is_accepted	True
best_oa_location.is_published	False
best_oa_location.raw_source_name
best_oa_location.landing_page_url	https://doi.org/10.1158/1078-0432.30710290
primary_location.id	doi:10.1158/1078-0432.30710290
primary_location.is_oa	True
primary_location.source
primary_location.license	cc-by
primary_location.pdf_url	https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_S5_from_Anlotinib_in_Locally_Advanced_or_Metastatic_Radioiodine-Refractory_Differentiated_Thyroid_Carcinoma_A_Randomized_Double-Blind_Multicenter_Phase_II_Trial/30710290/1/files/59835124.pdf
primary_location.version	acceptedVersion
primary_location.raw_type	posted-content
primary_location.license_id	https://openalex.org/licenses/cc-by
primary_location.is_accepted	True
primary_location.is_published	False
primary_location.raw_source_name
primary_location.landing_page_url	https://doi.org/10.1158/1078-0432.30710290
publication_date	2025-11-25
publication_year	2025
referenced_works_count	0
abstract_inverted_index.4	30
abstract_inverted_index.at	28
abstract_inverted_index.in	2
abstract_inverted_index.of	5, 8
abstract_inverted_index.and	15
abstract_inverted_index.for	11
abstract_inverted_index.sum	4
abstract_inverted_index.the	3, 12, 16
abstract_inverted_index.red:	20
abstract_inverted_index.blue:	24
abstract_inverted_index.group	14
abstract_inverted_index.least	29
abstract_inverted_index.group.	18
abstract_inverted_index.stable	25
abstract_inverted_index.target	9
abstract_inverted_index.changes	1
abstract_inverted_index.disease	26
abstract_inverted_index.lasting	27
abstract_inverted_index.lesions	10
abstract_inverted_index.longest	6
abstract_inverted_index.partial	22
abstract_inverted_index.placebo	17
abstract_inverted_index.Purplish	19
abstract_inverted_index.anlotinib	13
abstract_inverted_index.confirmed	21
abstract_inverted_index.diameters	7
abstract_inverted_index.response;	23
abstract_inverted_index.<p>Best	0
abstract_inverted_index.week.</p>	31
cited_by_percentile_year
countries_distinct_count	0
institutions_distinct_count	13
citation_normalized_percentile